Clinical Trials Directory

We are doing this study to find out if an experimental drug called BBI-355 (the study drug) is a safe and effective option for people with solid tumor forms of cancer. We also want to know the best dosing strategy for the drug. We plan to have later parts of this study that will look at how the study drug works when it is given with other cancer drugs.

We are doing this study to find out if adding azithromycin to the routine single antibiotic preventative therapy can lower the risk of developing infections after a cesarean delivery.

We are doing this study to learn more about how 2 different classes of diabetes medications help lower the risk of heart disease. The types of diabetes medications that have been shown to reduce the risk of new or worsening heart disease are SGLT2 inhibitors and GLP-1 receptor agonists. We don't know which of these drugs might be preferable to reduce heart disease risk for diabetes patients, and we hope this study can help us find out which drug(s) may be the most appropriate for most patients.

We are doing this study to find out if we can identify biomarkers that indicate the presence of ovarian cancer or indicate that it is likely to develop. Biomarkers are substances that can be released from cancer cells into the blood and can provide information on the following things: changes to someone's genes or DNA, how cancer cells will respond to cancer treatment, and whether cells are becoming resistant (no longer responding) to cancer treatment.

We are doing this study to find out whether it is possible to use genetic information from your tumor sample in order to test if your tumor will be sensitive to oxaliplatin (the standard of care treatment for your disease).

We are doing this study to get a better understanding of what predicts severe pain in teenagers and young adults living with sickle cell disease.

We are doing this study is to compare the two most common corrective surgeries in the U.S. for uterovaginal prolapse (UVP). For now, no high-quality data exists to help guide patients and surgeons on the best option for treatment of UVP. The goal of the study is to find out which surgery works best from a patient's perspective and has the lowest number of short-term and long-term medical problems.

We are doing this study to find the most effective, safe dose of an experimental drug called ONC-392 (the study drug). We want to know how well it works compared to the standard chemotherapy drug, docetaxel, for treating NSCLC.